Last10K.com

Aravive, Inc. (ARAV) SEC Filing 8-K Material Event for the period ending Monday, March 21, 2022

Aravive, Inc.

HISTORY TOOLS
CIK: 1513818 Ticker: ARAV

View differences made from one to another to evaluate Aravive, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aravive, Inc..

Continue

Assess how Aravive, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aravive, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Document And Entity Information

Material Contracts, Statements, Certifications & more

Aravive, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Material Contract
Exhibit 99.1: Additional Exhibits
Ticker: ARAV
CIK: 1513818
Form Type: 8-K Corporate News
Accession Number: 0001437749-22-006912
Submitted to the SEC: Tue Mar 22 2022 4:06:03 PM EST
Accepted by the SEC: Tue Mar 22 2022
Period: Monday, March 21, 2022
Industry: Pharmaceutical Preparations
Events:
  1. Event for Officers
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/arav/0001437749-22-006912.htm